Black Diamond Therapeutics, a precision oncology company based in Cambridge, has raised $85 million from a Series C financing round led by Boxer Capital of the Tavistock Group. Additional new investors in the Series C round included Wellington Management Company, BVF Partners, Deerfield Management, funds managed by Janus Henderson Investors, Logos Capital, and Casdin Capital. […]
US biodata company Gatehouse Bio is joining forces with pharma giant AstraZeneca to accelerate the discovery of new drugs for respiratory and cardiovascular diseases using sRNAlytics, the former’s artificial intelligence (AI)-driven platform. According to Gatehouse Bio, the sRNAlytics platform is capable of identifying new small RNA (sRNA) signatures and can illuminate molecular pathways correlated to […]
Continue reading …Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to jointly invest more than $570 million in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy. Currently, nadofaragene firadenovec is in late-stage development for the treatment of patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). […]
Continue reading …Novartis acquisition of The Medicines Company : Swiss drugmaker Novartis signed a deal worth $9.7 billion to acquire US biopharma company The Medicines Company, as per the latest pharma acquisition news. As per the terms of the all-cash deal, Novartis will acquire The Medicines Company for $85.00 per share. The Medicines Company, which is headquartered […]
Continue reading …Bristol-Myers Squibb has wrapped up its $74 billion acquisition of Celgene having got regulatory approval from all government authorities necessary for closing the merger agreement along with approvals from stockholders of the two companies. Celgene has now become a fully-owned subsidiary of Bristol-Myers Squibb and as per the merger terms, shareholders of the former have […]
Continue reading …Recipharm acquisition of Consort Medical : Swedish pharma group Recipharm has agreed to acquire Consort Medical, a British contract development and manufacturing organization (CDMO) for £505 million, as per the latest pharma acquisition news. The transaction is said to help Recipharm become a major inhalation company and places it among the top five CDMO players […]
Continue reading …Alkermes acquisition of Rodin Therapeutics : Irish biopharma company Alkermes has agreed to acquire Boston-based neuroscience company Rodin Therapeutics in a deal worth up to $950 million as per the latest pharma acquisition news. Rodin Therapeutics is engaged in developing novel, small molecules for the treatment of synaptopathies. Alkermes acquisition of Rodin Therapeutics is said […]
Continue reading …Bristol-Myers Squibb acquisition of Celgene : US pharma giant Bristol-Myers Squibb said that the US Federal Trade Commission (FTC) has given its clearance for its previously announced $74 billion acquisition of American biotech company Celgene. The FTC has accepted the proposed consent order regarding the pending merger of Bristol-Myers Squibb and Celgene, thereby allowing the […]
Continue reading …Roche acquisition of Promedior : Swiss drugmaker Roche has agreed to acquire Massachusetts-based biotech company Promedior in a deal worth up to $1.39 billion, as per the latest pharma acquisition news. The acquisition will give full rights for the Swiss pharma giant to Promedior’s portfolio of molecules targeting serious fibrotic diseases, including PRM-151, which holds […]
Continue reading …Merck acquisition of Calporta : Merck has acquired Calporta Therapeutics from COI Pharmaceuticals in a deal worth up to $576 million, as per the latest pharma acquisition news. Calporta Therapeutics, which was launched in early 2015, is engaged in the development of selective small-molecule agonists to TRPML1. According to COI Pharmaceuticals, TRPML1 is thought to […]
Continue reading …